JP2024519917A5 - - Google Patents

Info

Publication number
JP2024519917A5
JP2024519917A5 JP2023571950A JP2023571950A JP2024519917A5 JP 2024519917 A5 JP2024519917 A5 JP 2024519917A5 JP 2023571950 A JP2023571950 A JP 2023571950A JP 2023571950 A JP2023571950 A JP 2023571950A JP 2024519917 A5 JP2024519917 A5 JP 2024519917A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
subject
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519917A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030111 external-priority patent/WO2022246114A2/en
Publication of JP2024519917A publication Critical patent/JP2024519917A/ja
Publication of JP2024519917A5 publication Critical patent/JP2024519917A5/ja
Pending legal-status Critical Current

Links

JP2023571950A 2021-05-20 2022-05-19 リアノジン受容体モジュレーターを含む医薬組成物およびそれらの使用 Pending JP2024519917A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163191142P 2021-05-20 2021-05-20
US63/191,142 2021-05-20
PCT/US2022/030111 WO2022246114A2 (en) 2021-05-20 2022-05-19 Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof

Publications (2)

Publication Number Publication Date
JP2024519917A JP2024519917A (ja) 2024-05-21
JP2024519917A5 true JP2024519917A5 (cg-RX-API-DMAC7.html) 2025-05-23

Family

ID=84141833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571950A Pending JP2024519917A (ja) 2021-05-20 2022-05-19 リアノジン受容体モジュレーターを含む医薬組成物およびそれらの使用

Country Status (11)

Country Link
US (4) US11717526B2 (cg-RX-API-DMAC7.html)
EP (1) EP4340861A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024519917A (cg-RX-API-DMAC7.html)
KR (1) KR20240040681A (cg-RX-API-DMAC7.html)
CN (1) CN117750966A (cg-RX-API-DMAC7.html)
AU (1) AU2022279235A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024170A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176718A1 (cg-RX-API-DMAC7.html)
IL (1) IL308481A (cg-RX-API-DMAC7.html)
MX (1) MX2023013744A (cg-RX-API-DMAC7.html)
WO (1) WO2022246114A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022150603A1 (en) * 2021-01-08 2022-07-14 Armgo Pharma, Inc. Crystalline forms of a ryanodine receptor modulator and uses thereof
EP4433062A4 (en) * 2021-11-16 2025-10-22 Rycarma Therapeutics Inc THERAPEUTIC COMPOUNDS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920219A (ja) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd 腸溶性コ−テイング製剤の製造方法
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
JP4414237B2 (ja) 2002-03-20 2010-02-10 テバ ファーマシューティカル インダストリーズ リミティド ケチアピンヘミフマレートの結晶形
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
WO2008060332A2 (en) 2006-06-02 2008-05-22 The Trustees Of Columbia University In The City Of New York Methods for treating or reducing muscle fatigue
WO2008021439A2 (en) 2006-08-17 2008-02-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treatment of cardiac hypertrophy
WO2008021432A2 (en) 2006-08-17 2008-02-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treatment of conditions affecting the nervous system
WO2008144483A2 (en) 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
EA028108B1 (ru) 2008-03-03 2017-10-31 Армго Фарма, Инк. Способ получения бензотиазепинов из гамма-аминоалкилбензолов
WO2012037105A1 (en) 2010-09-14 2012-03-22 The Trustees Of Columbia University In The City Of New York Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases
EP2708535A1 (en) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
WO2015106268A1 (en) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
WO2016109596A1 (en) 2014-12-30 2016-07-07 Myotherix, Inc. Novel calcium modulators
JP6954927B2 (ja) * 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用

Similar Documents

Publication Publication Date Title
US20220168255A1 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
TWI468191B (zh) 有機化合物之調配物
EP2205279B1 (en) Pharmaceutical combination of aliskiren and valsartan
HUP0204409A2 (en) Sustained release ranolazine pharmaceutical compositions
CN101132777A (zh) 用于睡眠障碍的药物组合物
HUP0104088A2 (hu) Késleltetett felszabadulású ranolazinkészítmények alkalmazása
JP2007509155A5 (cg-RX-API-DMAC7.html)
US20030147957A1 (en) Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
JP2019529570A (ja) ミドドリンの組成物およびその使用方法
CA2606740A1 (en) Quinine-containing controlled-release formulations
CN114096530B (zh) 一种复合物的药物组合物及其制备方法
JP5362556B2 (ja) アリスキレンおよびヒドロクロロチアジドのガレヌス製剤
US20110123612A1 (en) Pharmaceutical preparation containing non-dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker
US20240366514A1 (en) Pharmaceutical compositions of ozanimod
CN101843892B (zh) 包括依那普利速释部分和非洛地平缓释部分的药物组合物制剂
US20110195117A1 (en) Controlled release compositions of ropinirole
JP2024539735A5 (cg-RX-API-DMAC7.html)
KR20090107960A (ko) 심혈관계 질환 치료용 약제학적 제제
HK1161125B (en) Galenic formulations comprising aliskiren